Phase II trial of mitoxantrone in head and neck cancer

Matti S. Aapro, David S Alberts

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mitoxantrone (1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.

Original languageEnglish (US)
Pages (from-to)329-330
Number of pages2
JournalInvestigational New Drugs
Volume2
Issue number3
DOIs
StatePublished - Sep 1984

Fingerprint

Mitoxantrone
Head and Neck Neoplasms
Lymphoma
Appointments and Schedules
Leukemia
Breast Neoplasms

Keywords

  • head and neck cancer
  • mitoxantone

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of mitoxantrone in head and neck cancer. / Aapro, Matti S.; Alberts, David S.

In: Investigational New Drugs, Vol. 2, No. 3, 09.1984, p. 329-330.

Research output: Contribution to journalArticle

@article{ffdcaa69fae7403da394523e345bf081,
title = "Phase II trial of mitoxantrone in head and neck cancer",
abstract = "Mitoxantrone (1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.",
keywords = "head and neck cancer, mitoxantone",
author = "Aapro, {Matti S.} and Alberts, {David S}",
year = "1984",
month = "9",
doi = "10.1007/BF00175386",
language = "English (US)",
volume = "2",
pages = "329--330",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of mitoxantrone in head and neck cancer

AU - Aapro, Matti S.

AU - Alberts, David S

PY - 1984/9

Y1 - 1984/9

N2 - Mitoxantrone (1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.

AB - Mitoxantrone (1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.

KW - head and neck cancer

KW - mitoxantone

UR - http://www.scopus.com/inward/record.url?scp=0021211990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021211990&partnerID=8YFLogxK

U2 - 10.1007/BF00175386

DO - 10.1007/BF00175386

M3 - Article

C2 - 6511239

AN - SCOPUS:0021211990

VL - 2

SP - 329

EP - 330

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -